CONCORDBIOUpdated 4 Sept 2026, 2:31

Concord Biotech Limited

CONCORDBIOUpdated 4 Sept 2026, 2:31

Market Cap

₹15,170Cr.

Current Price

₹1,448

High / Low

₹1,730/987

Stock P/E

53.4

ROE12.6%

ROCE17.4%

Book Value₹193

Face Value₹1.00

Dividend Yield0.52%

About

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Quarterly results

Last reported quarters₹ Cr.

Profit & loss

Annual statement₹ Cr.

Shareholding pattern

As of Jun 2026%

Shareholding trend

Ownership over time%

Balance sheet

Assets & liabilities₹ Cr.

Cash flows

Operating, investing & financing₹ Cr.

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	165	182	236	133	131	105	119	117	125	159	159
Inventory Days	276	321	381	310	312	503	434	430	331	286	483
Days Payable	108	129	210	112	201	152	185	190	150	135	150
Cash Conversion Cycle	334	374	407	331	242	456	368	357	306	310	492
Working Capital Days	195	209	275	177	159	177	163	153	166	193	231
ROCE %	—	37%	—	25%	25%	32%	21%	26%	28%	28%	17%

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 4 September 2026 at 2:31

CONCORD BIOTECH LIMITED (CONCORDBIO) financials — quarterly results, P&L, cash flow, balance sheet, shareholding